Percutaneous closure of hypertensive ductus arteriosus
- Carlos Zabal,
- José Antonio García-Montes,
- Alfonso Buendía-Hernández,
- Juan Calderón-Colmenero,
- Emilia Patiño-Bahena,
- Antonio Juanico-Enriquez,
- Fause Attie
- Correspondence to Carlos Zabal, Juan Badiano 1, Col. Sección XVI, Tlalpan, 14080 Mexico City, Mexico;
- Accepted 3 December 2009
Background The Amplatzer duct occluder (ADO) has been used with success to close large patent ductus arteriosus (PDA), but some problems exist especially with hypertensive PDAs, such as incomplete closure, haemolysis, left pulmonary artery stenosis, obstruction of the descending aorta and progressive pulmonary vascular disease.
Methods and results We analysed a group of 168 patients with isolated PDA and pulmonary artery systolic pressure (PSAP) ≥50 mm Hg. Mean age was 10.3 ± 14.3 years (median 3.9), PDA diameter was 6.4 ± 2.9 mm (median 5.9), PASP was 63.5 ± 16.2 mm Hg (median 60), Qp/Qs was 2.7 ± 1.2 (median 2.5), total pulmonary resistance index (PRI) was 3.69 ± 2.15 (median 3.35) and vascular PRI was 2.73 ± 1.72 (median 2.37). We used ADOs in 145 (86.3%) cases, Amplatzer muscular ventricular septal defect occluders (AMVSDO) in 18 (10.7%), Amplatzer septal occluders (ASO) in three (1.8%) and the Gianturco-Grifka device in two (1.2%) cases. Device diameter was 106.3% ± 51% higher than PDA diameter. PASP decreased after occlusion to 42.5 ± 13.3 mm Hg (p<0.00001). Immediately after closure, no or trivial shunt was present in 123 (74.5%) cases. Immediate complications were device embolisation in five (3%) cases and descending aortic obstruction in one case. The overall success rate was 98.2%. Follow-up in 145 (86.3%) cases for 37.1 ± 24 months (median 34.1) showed further decrease of the PASP to 30.1 ± 7.7 mm Hg (p<0.0001).
Conclusions Percutaneous treatment of hypertensive PDA is safe and effective. ADO works well for most cases, but sometimes other devices (MVSDO or ASO) have to be used. When cases are selected adequately, pulmonary pressures decrease immediately and continue to fall with time.
- Ductus arteriosus
- patent heart defects
- congenital hypertension
- pulmonary catheterisation occlusion
- paediatric interventional cardiology
- device closure
- pulmonary arterial hypertension (PAH)
Competing interests Dr Carlos Zabal is proctor and consultant for AGA Medical Corporation.
Ethics approval This study was conducted with the approval of the National Institute of Cardiology “Ignacio Chavez”.
Provenance and peer review Not commissioned; externally peer reviewed.